



## ICI PAKISTAN LTD.

ICI House, 5 West Wharf,  
Karachi 7400

T +92 21 3231 3717-22  
F +92 21 3231 1739  
UAN 111 100 200

[www.ici.com.pk](http://www.ici.com.pk)

## News Release

### **ICI Pakistan Limited strengthens its partnership with AstraZeneca UK Limited in Pakistan**

Karachi  
December 17, 2019

ICI Pakistan Limited (“ICI Pakistan”) and AstraZeneca UK Limited (“AstraZeneca”) today confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca’s high quality life-saving medicines. AstraZeneca GCC Country President Ismail Shehada visited ICI Pakistan and met with key stakeholders during his two-day visit to renew the existing relationship and explore potential new avenues of partnership to alleviate suffering and build a platform for patients and caregivers to treat high burden of diseases in Pakistan.

Gracing the ceremony at the ICI Pakistan Head Office, Mr. Mike Nithavrianakis, British Deputy High Commissioner Karachi and Trade Director for Pakistan, emphasised the importance of building a sustainable ecosystem to provide much needed care to patients in Pakistan.

Speaking on the occasion, ICI Pakistan Chief Executive Asif Jooma said, “ICI Pakistan has been in the pharmaceuticals business since 1993 and seeks to further enhance its global partnerships and introduce innovative products.”

Mr. Shehada added, “AstraZeneca has an interest in the region and intends to grow its business through providing improved solutions for patients.” He further stated, “AstraZeneca is a full healthcare company providing not only innovative molecules but which believes in going beyond medication alone by looking to introduce customised solutions to meet local needs and requirements.”

Mr. Shehada was accompanied by a delegation, which included AstraZeneca Commercial and Operations Director Gulf & Pakistan Khurram Hanif, Naila Hasan Business Manager Pakistan & Ghaleb Al Ahdab Communications Lead Gulf. ICI Pakistan Vice President

#### Safe Harbor Statement

This press release may contain statements, which address such key issues as ICI Pakistan Ltd.’s growth strategy, future financial results, market positions, product development, products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialised external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our latest Annual Report, a copy of which can be found on the Company’s corporate website [www.ici.com.pk](http://www.ici.com.pk)





## ICI PAKISTAN LTD.

ICI House, 5 West Wharf,  
Karachi 7400

T +92 21 3231 3717-22  
F +92 21 3231 1739  
UAN 111 100 200

[www.ici.com.pk](http://www.ici.com.pk)

### News Release

Pharmaceuticals Aamer Malik and General Manager Pharmaceuticals Ali Masood accompanied the delegation during meetings with various stakeholders, including the Secretary Ministry of Health, Chief Executive of the Drug Regulatory Authority of Pakistan (DRAP), physicians, and other caregivers in the healthcare system.

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

In recent years, ICI Pakistan Limited has increased its presence in the pharmaceuticals business by acquiring manufacturing facilities which are based in Karachi and Hattar, Khyber Pakhtunkhwa.

#### **About ICI Pakistan Limited:**

ICI Pakistan Limited is a leading Pakistan-based manufacturing and trading company consisting of four diverse Businesses: Polyester, Soda Ash, Chemicals & Agri Sciences, and Life Sciences. Through these Businesses, the Company manufactures and trades in a wide range of products including: polyester staple fibre (PSF), soda ash, general and specialty chemicals, toll-manufactured pharmaceuticals, nutraceuticals, animal health products and agricultural products (including chemicals, field crop seeds, vegetable seeds and more). The Company also has a management stake in the infant formula business under the name of NutriCo Pakistan Private Limited.

ICI Pakistan Limited is part of Yunus Brothers Group (YBG), one of the fastest-growing and most progressive Pakistani conglomerates with a wide portfolio of businesses including, but not limited to: cement, textiles, power generation and commodity trading.

For more information please visit: [www.ici.com.pk](http://www.ici.com.pk)

For further information, please contact:

#### **Nausheen Ahmad**

General Counsel, Company Secretary and Head of Corporate Communications & Public Affairs

ICI Pakistan Limited

021-111-100-200

[Nausheen.Ahmad@ici.com.pk](mailto:Nausheen.Ahmad@ici.com.pk)

#### Safe Harbor Statement

This press release may contain statements, which address such key issues as ICI Pakistan Ltd.'s growth strategy, future financial results, market positions, product development, products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialised external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our latest Annual Report, a copy of which can be found on the Company's corporate website [www.ici.com.pk](http://www.ici.com.pk)

